IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 14.690-14.940 for the period, compared to the consensus EPS estimate of 14.640. The company issued revenue guidance of $4.7 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several analyst reports. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group reduced their price target on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a research report on Monday, July 27th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $749.00.

IDEXX Laboratories Price Performance

Shares of IDXX stock traded up $31.98 during trading hours on Tuesday, hitting $599.82. The company’s stock had a trading volume of 745,250 shares, compared to its average volume of 580,174. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The business has a fifty day moving average of $557.53 and a 200-day moving average of $588.43. The stock has a market cap of $47.31 billion, a price-to-earnings ratio of 44.23, a P/E/G ratio of 3.06 and a beta of 1.54. IDEXX Laboratories has a twelve month low of $518.55 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. During the same period last year, the firm earned $3.50 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories will post 14.68 EPS for the current year.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q2 earnings beat expectations: IDEXX reported adjusted earnings of $4.27 per share, exceeding analyst estimates near $3.94–$3.95. Quarterly revenue reached approximately $1.22 billion, also topping expectations and increasing 10% year over year. Why Is IDEXX Laboratories Stock Gaining Tuesday?
• Positive Sentiment: Broad-based organic growth supported the results: Companion Animal Group revenue increased 9% organically, while Water revenue rose 13% and Livestock, Poultry and Dairy revenue grew 9% organically. The performance indicates continued demand for IDEXX’s veterinary diagnostics and testing products. IDEXX Laboratories Announces Second Quarter Results
• Positive Sentiment: Full-year guidance moved above consensus: IDEXX set fiscal 2026 EPS guidance at $14.69–$14.94, compared with the $14.64 analyst consensus. Revenue guidance of roughly $4.7 billion was consistent with expectations, suggesting the main upside came from profitability and earnings execution. IDEXX Laboratories shares climb after earnings beat and improved full-year outlook
• Neutral Sentiment: Investor focus remains on valuation and execution: The stock trades at a high earnings multiple, while its recent trading level is near its 200-day moving average and below its 12-month high. The earnings beat and outlook increase optimism, but sustained gains will depend on maintaining growth and margin performance.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IDXX. State Street Corp boosted its stake in shares of IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after buying an additional 138,956 shares during the last quarter. Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after buying an additional 181,955 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of IDEXX Laboratories by 37.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 952,223 shares of the company’s stock worth $644,208,000 after buying an additional 258,015 shares in the last quarter. Wellington Management Group LLP raised its position in IDEXX Laboratories by 318.1% in the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after acquiring an additional 592,834 shares in the last quarter. Finally, Amundi grew its holdings in shares of IDEXX Laboratories by 4.4% in the 4th quarter. Amundi now owns 618,743 shares of the company’s stock worth $418,598,000 after acquiring an additional 26,144 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.